About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our main scientific interest is to understand, from a multidisciplinary and translational approach, the molecular and cellular processes leading to renal dysfunction in several kidney pathologies. Specifically, our research lines are
We are experts on the following areas:
To sum up, our research main objective is to combine –omic data from cellular and animal models with patients’ data to identify novel biomarkers and possible treatments for several renal diseases.
PMID: 35137195 Journal: NEPHROLOGY DIALYSIS TRANSPLANTATION Year: 2022 Reference: Nephrol Dial Transplant. 2022 Nov 23;37(12):2474-2486. doi: 10.1093/ndt/gfac029. Impact factor: Publication type: Paper in international publication Authors: Alpay, Harika; Amouzegar, Atefeh; Ariceta, Gema; Atmis, Bahriye; Bacchetta, Justine; Barany, Peter; Baron, Stephanie; Bayrakci, Umut Selda; Belge, Hendrica; Besouw, Martine et al. DOI: 10.1093/ndt/gfac029
PMID: 35131032 Journal: eLife Year: 2022 Reference: Elife. 2022 Feb 8;11. pii: 73926. doi: 10.7554/eLife.73926. Impact factor: Publication type: Paper in international publication Authors: Alonso-Maranon, Josune; Cantero-Recasens, Gerard; Espinosa, Lluis; Garrido, Marta; Iglesias, Mar; Lobo-Jarne, Teresa; Malhotra, Vivek et al. DOI: 10.7554/eLife.73926
PMID: 34352790 Journal: UROLOGIA INTERNATIONALIS Year: 2022 Reference: Urol Int. 2022;106(2):154-162. doi: 10.1159/000517543. Epub 2021 Aug 5. Impact factor: Publication type: Paper in international publication Authors: Aula Olivar, Ana; Carrion Puig, Albert; De Torres Ramirez, Ines M; Lozano Palacio, Fernando; Raventos Busquets, Carles X; Semidey, M Eugenia; Trilla Herrera, Enrique et al. DOI: 10.1159/000517543
PMID: 34554648 Journal: AMERICAN JOURNAL OF TRANSPLANTATION Year: 2022 Reference: Am J Transplant. 2022 Feb;22(2):673-675. doi: 10.1111/ajt.16855. Epub 2021 Oct 5. Impact factor: Publication type: Letter or abstract Authors: Bestard, Oriol; Campins, Magda; Campos-Varela, Isabel; Castells, Lluis; Crespo, Elena; Esperalba, Juliana; Jouve, Thomas; Len, Oscar; Lopez, Manuel; Moreso, Francesc et al. DOI: 10.1111/ajt.16855
PMID: 33595712 Journal: PEDIATRIC NEPHROLOGY Year: 2021 Reference: Pediatr Nephrol. 2021 Oct;36(10):3045-3055. doi: 10.1007/s00467-021-04968-2. Epub 2021 Feb 17. Impact factor: Publication type: Review in international publication Authors: Ariceta, Gema; Madariaga, Leire; Vall-Palomar, Monica et al. DOI: 10.1007/s00467-021-04968-2
PMID: 33535736 Journal: Turkish Journal Of Medical Sciences Year: 2021 Reference: Turk J Med Sci. 2021 Dec 13;51(6):2881-2886. doi: 10.3906/sag-2012-26. Impact factor: Publication type: Paper in international publication Authors: Ariceta, Gema; Askiti, Varvara; Aufricht, Christoph; BakkaloGlu EzgU, Sevcan AzIme; Canpolat, Nur; Dufek, Stephanie; Edefonti, Alberto; EkIm, MesIha; Fischbach, Michel; Holtta, Tuula et al. DOI: 10.3906/sag-2012-26
PMID: 33509356 Journal: KIDNEY INTERNATIONAL Year: 2021 Reference: Kidney Int. 2021 Feb;99(2):324-335. doi: 10.1016/j.kint.2020.10.035. Impact factor: Publication type: Paper in international publication Authors: Ariceta, Gema; Bertholet-Thomas, Aurelia; Bockenhauer, Detlef; Calo, Lorenzo A; Capasso, Giovambattista; Emma, Francesco; Konrad, Martin; Nijenhuis, Tom; Schlingmann, Karl P; Singh, Mandeep et al. DOI: 10.1016/j.kint.2020.10.035
PMID: 33492457 Journal: PEDIATRIC NEPHROLOGY Year: 2021 Reference: Pediatr Nephrol. 2021 Apr;36(4):1025-1028. doi: 10.1007/s00467-020-04906-8. Epub 2021 Jan 25. Impact factor: Publication type: Paper in international publication Authors: Ariceta, Gema; Chocron, Sara; Ferrer, Roser; Giralt, Marina et al. DOI: 10.1007/s00467-020-04906-8
The communication is part of a study aimed at identifying the mechanisms of progression of Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis, a rare disease that affects the kidneys.
"Patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis present miRNA profiles in urinary extracellular vesicles associated with disease progression" was the awarded work.
Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation.
